IMPACT EU Post-Market Clinical Follow-Up Study
Left Ventricular Dysfunction
About this trial
This is an interventional treatment trial for Left Ventricular Dysfunction
Eligibility Criteria
Inclusion Criteria: Hemodynamically stable patients undergoing one (1) of the following cardiac surgery procedures on CPB including aortic cross-clamping and cardioplegic arrest Isolated CABG Isolated mitral valve repair or replacement (MVR) Mitral and tricuspid valve repair or replacement (MVR/TVR) CABG and mitral valve repair or replacement (CABG/MVR) CABG and mitral valve repair or replacement and tricuspid valve repair or replacement (CABG/MVR/TVR) CABG and tricuspid valve repair or replacement (CABG/TVR) LVEF within 30 days before surgery of either: ≤30% measured by echocardiogram or LVEF ≤35% as above for patients with significant mitral regurgitation (MR 3+ or 4+; see definition) and planned corrective mitral valve surgery (including MV replacement or repair) Age 18 years or older Subject has signed informed consent form and is willing and able to attend all follow-up visits and to perform all tests. Patient is eligible to receive the Impella 5.5 as per the current IFU. Exclusion Criteria: Salvage operation (cardiac arrest within 24 hours prior to index surgery) Unresponsive state within 24 hours of the time of surgery Cardiogenic shock at the time of index surgery Any mechanical MCS device (such as IABP, ECMO, Impella®, CentriMag™ or TandemHeart®) in place prior to informed consent RV dysfunction requiring mechanical or inotropic support preoperatively and/or likely to be needed postoperatively Index procedures requiring total circulatory arrest (TCA), such as aortic arch replacement, planned durable LVAD, durable RVAD, planned right-sided temporary mechanical support of any kind, total artificial heart (TAH), cardiac transplantation, pericardiectomy, pulmonary thromboendarterectomy and septal myectomy Restrictive or obstructive cardiomyopathy, constrictive pericarditis, restrictive pericarditis, pericardial tamponade or other conditions in which cardiac output is dependent on venous return Ventricular septal defect (VSD) Stroke within 30 days of the index cardiac surgical procedure Prior mantle field chest irradiation Prior solid organ or hematologic transplantation (heart, kidney, liver, lung, pancreas, bone marrow) or durable LVAD History of chronic dialysis Pre-existing liver dysfunction defined as Child-Pugh Class B or C Pre-existing pulmonary disease requiring home oxygen, or "severe pulmonary disease" determined by enrolling investigator Systemic active infection or evidence of systemic bacterial, fungal or viral infection within 72 hours before surgery (blood culture positive with leukocytosis) Confirmed COVID-19 infection within two (2) weeks prior to operation Pregnant or planning pregnancy within next 12 months. NOTE: Female patients of childbearing potential need to have a negative pregnancy test performed within 14 days prior to intervention. Participation in the active treatment or follow-up phase of another interventional clinical trial of an investigational drug or device which has not reached its primary endpoint Known contraindication to heparin; History of bleeding diathesis or known coagulopathy or will refuse blood transfusions Inability to perform aortic cross-clamp, such as due to porcelain aorta Any contraindication or condition that would prevent the ability to place Impella 5.5® (per current IFU), including LV thrombus and/or presence of a mechanical aortic valve Any organ condition, concomitant disease (e.g., psychiatric illness, current severe alcoholism or current drug abuse, cancer, hepatic or kidney disease), with life expectancy of ≤2 years or other abnormality that itself or the treatment of which, could interfere with the conduct of the trial or that, in the opinion of the investigator would pose an unacceptable risk to the subject in the trial. Subject has other medical, social or psychological problems that, in the opinion of the investigator, compromises the subject's ability to give written informed consent and/or to comply with trial procedures, including patients under guardianship Any subject considered to be part of a vulnerable population (as per ISO 14155)
Sites / Locations
- Universitätsklinikum Heidelberg - Klinik für Herzchirurgie
- RWTH Uniklinik Aachen - Klinik für HerzchirurgieRecruiting
- Universitätsmedizin Halle/Saale - Klinik für HerzchirurgieRecruiting
- UKSH Campus Kiel - Klinik für Herz- und GefäßchirurgieRecruiting
- Deutsches Herzzentrum der CharitéRecruiting
- Universitäres Herz- und Gefäßzentrum Hamburg - Klinik und Poliklinik für Herz- und GefäßchirurgieRecruiting
Arms of the Study
Arm 1
Other
Treatment with Impella 5.5 System